1. Introduction {#sec1-medicina-55-00409}
===============

The *CLDN16* gene is clustered on chromosome 3q28 and encodes the claudin16 protein which is found primarily in the kidneys, specifically in the thick ascending limb (TAL) of the loop of Henle where it regulates the paracellular resorption of magnesium ions. The defects in the *CLDN16* gene are a cause of primary hypomagnesemia (FHHNC) (OMIM \# 248250; HOMG3), which is characterized by massive renal magnesium wasting with hypomagnesemia and hypercalciuria resulting in nephrocalcinosis and renal failure (Entrez gene summary: <https://www.ncbi.nlm.nih.gov/gene/10686>). The mutations in the gene encoding the claudin19 protein can also result in the aforementioned renal disorder although, in this case, the disease phenotype is also complicated by ocular involvement (OMIM \# 248190; HOMG5). The renal prognosis for both types is poor, with progressive chronic kidney disease requiring renal replacement therapy usually presenting in the second or third decade of life \[[@B1-medicina-55-00409]\].

The mutations in *CLDN16* and *CLDN19* occur throughout the coding region and can affect proper folding, intracellular trafficking of the protein or its paracellular pore forming function \[[@B2-medicina-55-00409]\]. Regarding, in particular, the impact of *CLDN16* mutations on protein function, a genotype/phenotype correlation has been proposed reflecting the severity of FHHNC \[[@B3-medicina-55-00409]\]. The possible contribution of epigenetic factors or genetic modifiers on the phenotypic variability observed in some patients with FHHNC has also been proposed, although no studies have addressed this hypothesis \[[@B4-medicina-55-00409]\].

More than 50 pathogenic mutations have been reported so far, including mainly missense/nonsence mutations, splice-site mutations and small deletions of the *CLDN16* gene, yet the pathophysiology of the disease remains obscure \[[@B4-medicina-55-00409]\]. It has been shown that disease-associated mutations affect either the intracellular traffic of CLDN16 or its capacity to facilitate paracellular Mg^2+^ transport \[[@B5-medicina-55-00409]\]. The mutant CLDN16 molecules of the first category accumulate in different intracellular compartments of the exocytic and/or endocytic pathways while those included in the second category are correctly delivered to the tight junction (TJ) but are defective in Mg^2+^ permeability \[[@B5-medicina-55-00409]\]. It has been reported that most of mutations in the *CLDN16* gene of FHHNC patients and dephosphorylation of CLDN16 induce abnormal cytoplasmic localization \[[@B6-medicina-55-00409]\].

Notably, the CLDN16 mutants which are distributed in the TJ have full or partial function in contrast with the ones that are mislocalized to the cytoplasmic compartments (endoplasmic reticulum, Golgi apparatus, lysosomes) which are not functional \[[@B6-medicina-55-00409]\]. Although the mislocalization of CLDN16 leads to loss of its function, the mechanism of its transport has not yet been clarified \[[@B6-medicina-55-00409]\].

Taking into account the above observations, this study aimed to perform an in-depth computational analysis of the CLDN16 gene and protein, focusing specifically on the prediction of the latter's subcellular location in order to gain a better understanding about the mechanisms by which *CLDN16* mutations can induce renal diseases.

2. Materials and Methods {#sec2-medicina-55-00409}
========================

The nucleotide sequence of the *CLDN16* gene was downloaded in FASTA format from the Ensembl database. The EMBOSS_CpGplot tool \[[@B7-medicina-55-00409]\] was employed to identify putative CpG islands using the criteria by Takai and Jones \[[@B8-medicina-55-00409]\]: Observed/expected ratio \>0.65; percent C + percent G \>55.00; length \>500.

The prediction of promoters and enhancers was performed by the FPROM database \[[@B9-medicina-55-00409]\]. The GeneMania database was used for the prediction of the *CLDN16* gene interactors \[[@B10-medicina-55-00409]\]. The description of the retrieved genes was provided by the GeneCards database \[[@B11-medicina-55-00409]\]. The functional enrichment analysis of gene ontology (GO) annotations relative to disease of the *CLDN16* interactome was performed using ToppFun, an application of the ToppGene Suite \[[@B12-medicina-55-00409]\].

Similarly, the amino acid sequence of the CLDN16 protein was downloaded in FASTA format from the Uniprot database (UniProtKB ID: Q9Y5I7). The ProtParam tool was used for the prediction of the protein's physicochemical properties \[[@B13-medicina-55-00409]\]. The SignalP v.4.1 Server carried out the prediction of the presence and location of signal peptide cleavage sites \[[@B14-medicina-55-00409]\]. The combined transmembrane topology and signal peptide prediction was performed by the Phobius database \[[@B15-medicina-55-00409]\]. The protein subcellular location was predicted by WoLFPSORT \[[@B16-medicina-55-00409]\]. MitoProt II and Mitofates were used for the identification of putative mitochondrial targeting sequences and cleavage sites \[[@B17-medicina-55-00409],[@B18-medicina-55-00409]\]. The prediction of the secondary structure was performed by the PSIPRED v.3.3 database as the latter also provides the possibility of identifying disordered protein regions through the disorder predictor tool DISOPRED2 \[[@B19-medicina-55-00409]\]. The prediction of protein knots was conducted using the KnotProt v.2.0 database \[[@B20-medicina-55-00409]\]. The DISPHOS v.1.3 database was used to predict serine, threonine and tyrosine phosphorylation sites within the CLDN16 protein selecting transport as the latter's functional category \[[@B21-medicina-55-00409]\].

The identification of predicted and validated *CLDN16*-miRNA targets was performed by the miRWalk v.2.0 database using the default parameters (3'UTR, start position of miRNA seed=position 1, minimum seed length=7) \[[@B22-medicina-55-00409]\].

The selection of the aforementioned bioinformatic tools was made mainly on the basis of two factors: Performance and quality of documentation. All analyses were performed on September 2018. The specific versions of the databases have been indicated in the cases where more than one version is available. The workflow of the in-silico methodology used in this study is visualized in [Figure 1](#medicina-55-00409-f001){ref-type="fig"}.

3. Results {#sec3-medicina-55-00409}
==========

3.1. CLDN16 Gene {#sec3dot1-medicina-55-00409}
----------------

One CpG island was identified in the nucleotide sequence of the *CLDN16* gene ([Figure 2](#medicina-55-00409-f002){ref-type="fig"}). Twenty five promoters/enhancers were predicted in the FPROM analysis ([Table 1](#medicina-55-00409-t001){ref-type="table"}). The GeneMania database identified 20 genes as possible interactors of the *CLDN16* gene ([Table 2](#medicina-55-00409-t002){ref-type="table"}). According to ToppFun, the *CLDN16* interactome is mainly involved in kidney disorders ([Table 3](#medicina-55-00409-t003){ref-type="table"}).

3.2. CLDN16 Protein {#sec3dot2-medicina-55-00409}
-------------------

The ProtParam Tool predicted that the CLDN16 protein has a theoretical isoelectric point and an instability index equal to 8.26 and 35.14 respectively. The latter value classifies the protein as stable. No signal peptide cleavage site was identified by the SignalP v.4.1 Server and the Phobius database. The results of the combined transmembrane topology and signal peptide prediction analysis as retrieved by the latter database are presented in [Figure 3](#medicina-55-00409-f003){ref-type="fig"}. The WoLFPSORT database identified 32 nearest neighbors (plasma membrane: 19, extracellular: 8, mitochondrial: 2, nuclear: 1, peroxisomal: 1, golgi: 1). MitoProt II predicted a probability of export to mitochondria equal to 0.9740 while Mitofates identified a cleavable localization signal in the N terminal of the CLDN16 protein (22 MPP cleavage site). The secondary structure prediction is shown in [Figure 4](#medicina-55-00409-f004){ref-type="fig"}. The KnotProt v.2.0 database did not predict any knot or slipknot in the protein structure of CLDN16. Νo phosphorylation sites were identified within the CLDN16 protein region by applying DISPHOS 1.3 to the functional class of transport ([Figure 5](#medicina-55-00409-f005){ref-type="fig"}).

3.3. miRNA Analysis {#sec3dot3-medicina-55-00409}
-------------------

The miRWalk v.2.0 database predicted that *CLDN16* was most probably a target of the miRNAs presented in [Table 4](#medicina-55-00409-t004){ref-type="table"}.

4. Discussion {#sec4-medicina-55-00409}
=============

In this study we aimed to perform an in-depth computational study of the CLDN16 gene and protein so as to gain a better understanding about the latter's involvement in the pathophysiology of renal disorders. Due to the fact that mislocalized CLDN16 mutants lose their function \[[@B6-medicina-55-00409]\], this study focused specifically in the prediction of the protein's subcellular location. Our results, which have been reproduced in two independent databases, are the first to identify mitochondria as a probable cytoplasmic compartment for CLDN16 localization, thus providing new insights into the protein's intracellular transport. Additionally, no signal peptide cleavage site was identified. The integral membrane proteins carry a signal peptide and/or a transmembrane domain that mediates their insertion into the endoplasmic reticulum from where they exit to reach the Golgi apparatus and the plasma membrane \[[@B23-medicina-55-00409]\]. Two questions arise from the above findings: 1. What is the functional role of the CLDN16 protein in mitochondria, assuming the latter actually locates at this site? 2. Which are the processes that control the protein's translocations?

The regulation of protein trafficking relies on information that is encoded within the protein sequence and occurs by two major mechanisms, namely co-translational and post-translational translocation \[[@B24-medicina-55-00409]\]. CLDN16 is located in the TJs but the mechanism regulating its localization is unclear \[[@B25-medicina-55-00409]\]. It has been reported that in renal tubular epithelial cells the tight junctional localization of CLDN16 is regulated by Syntaxin 8 (STX8) \[[@B6-medicina-55-00409]\]. In addition, the association between the two proteins requires the phosphorylation of CLDN16 \[[@B6-medicina-55-00409]\]. The dephosphorylation of CLDN16 increases its intracellular distribution and decreases paracellular Mg^2+^ permeability \[[@B25-medicina-55-00409]\]. The RING finger-and PDZ domain-containing protein PDZRN3 mediates the endocytosis of dephosphorylated CLDN16, thus representing an important component of the CLDN16-trafficking machinery in the kidney \[[@B25-medicina-55-00409]\]. Notably, in this study, no phosphorylation sites were identified within the CLDN16 protein region by applying DISPHOS to the functional protein category of transport. This is important as DISPHOS uses disorder information to improve the distinction between phosphorylation and non-phosphorylation sites \[[@B21-medicina-55-00409]\]. Based on both our findings and the existing literature, we could speculate that the dephosphorylated form of the CLDN16 protein may translocate to the mitochondria although cellular subfractionation studies need to be performed in order to prove this hypothesis. In addition, it would be of interest to see whether the protein as a whole or a fraction of it, as in the case of the retinoblastoma protein, reaches the mitochondria compartment \[[@B26-medicina-55-00409]\].

The presence of mutations leading to defects in protein trafficking is an acknowledged pathogenetic mechanism observed in an increasing number of disorders, including approximately one third of monogenic diseases affecting the kidneys \[[@B27-medicina-55-00409]\]. In the case of the FHHNC disease, various mutations in the *CLDN16* gene can lead either to the retention of the protein product in the endoplasmic reticulum and Golgi compartments or to its mislocalization to lysosome \[[@B27-medicina-55-00409]\]. Notably, the *CLDN16* gene interaction network appears to be associated with Bartter syndrome type 4, which results from mutations in the *BSND* gene also affecting the trafficking and function of CIC-K channels \[[@B28-medicina-55-00409],[@B29-medicina-55-00409]\]. The remaining results of the functional analysis are also intriguing as they link the *CLDN16* interactome with disorders of water, electrolytes and acid-base metabolism. The epithelial cells in the TAL, form a water-impermeable barrier, actively transport Na^+^ and CI^−^ via the transcellular route and provide a paracellular pathway for the selective reabsorption of Mg^2+^ and Ca^2+^ \[[@B30-medicina-55-00409]\]. An interesting study relating to salt and acid-base metabolism in *CLDN16* knockdown mice, revealed that the loss of *CLDN16* results in increased urinary flow, reduced HCO3- excretion and lower urine pH \[[@B31-medicina-55-00409]\].

The identification, in this work, of *CLDN19* and *CLDN14* as members of the *CLDN16* gene regulatory network denotes the functional interplay of these genes, which has been confirmed in previous studies \[[@B30-medicina-55-00409],[@B32-medicina-55-00409]\]. It has been reported that the CLDN14 protein blocks the paracellular cation channel formed by the CLDN16-CLDN19 protein complex that is critical for Ca^2+^ reabsorption in the TAL \[[@B32-medicina-55-00409]\]. Of interest, the gene expression of *CLDN14* is regulated on the post-transcriptional level by two microRNAs (miR-9 and miR-374) which directly target the 3′-UTR of the CLDN14 mRNA inducing its decay and translational repression \[[@B30-medicina-55-00409],[@B32-medicina-55-00409]\]. The Ca^2+^ sensing receptor (CaSR) acts upstream of the microRNA-CLDN14 axis \[[@B32-medicina-55-00409]\] providing thus a regulatory loop to maintain Ca^2+^ homeostasis in the kidney \[[@B30-medicina-55-00409]\]. Another finding that should be commented upon, pertaining to the *CLDN16* gene interaction network, is the identification of the *CLDN10* gene as recently it was reported that deletion of the latter rescues *CLDN16*-deficient mice from hypomagnesemia and hypercalciuria \[[@B33-medicina-55-00409]\]. It is worth noting that the four aforementioned *CLDN* genes have been included in a list of 16 genes (both differentially expressed and differentially methylated) which ranked in the top 15% of the nodes of an integrated gene regulatory network in kidney renal clear cell carcinoma \[[@B34-medicina-55-00409]\]. We currently perform an in-silico transcriptomic analysis of the *CLDN16* interactome in kidney cancer to examine possible associations.

With respect to the miRNA analysis results, this study predicted seven putative miRNA bindind sites within the 3'-UTR region of CLDN16. The miRNAs partake in the regulation of almost every cellular process and are associated with many human pathologies including kidney diseases \[[@B35-medicina-55-00409]\]. In the TAL of the loop of Henle, miRNAs not only regulate the Ca^2+^ metabolism as mentioned above, but also the salt and fluid handling \[[@B35-medicina-55-00409]\]. This was evidenced in a study which demonstrated that the miR-192 suppresses the β-1 subunit of Na(+)/K(+)-ATPase, the enzyme that provides the driving force for tubular transport \[[@B36-medicina-55-00409]\]. To our knowledge, no literature exists with respect to the miRNAs that have been identified in this study and FHHNC disease. Recently, a group from Spain standardized the protocol conditions for the identification of differentially expressed miRNAs in urinary exosome-like vesicles of FHHNC patients (and other renal diseases) characterized by polyuria \[[@B37-medicina-55-00409]\].

The CpG islands are sites of transcription initiation \[[@B38-medicina-55-00409]\] and have been characterized lately as "hotspots for global gene regulation" \[[@B39-medicina-55-00409]\]. At the same time, promoters and enhancers are DNA regulatory regions accountable for ensuring proper spatiotemporal expression patterns of eukaryotic genes \[[@B40-medicina-55-00409]\]. Most genes have multiple promoters and 72% of human promoters are associated with CpG islands \[[@B41-medicina-55-00409]\]. The frequency of TATA box containing promoters among human protein-coding genes has been reported to be 10--20% with the result that the majority of protein-coding genes are regulated by TATA-less promoters \[[@B41-medicina-55-00409]\]. The FPROM method which has been used in this study for the identification of potential transcription start positions has been shown to predict with high accuracy both types of promoters \[[@B9-medicina-55-00409]\]. The identification in this study of seven miRNA binding sites along with the prediction of one CpG island and twenty five promoters/enhancers within the nucleotide sequence of the *CLDN16* gene provides the clue that the latter's expression is possibly strictly regulated at the transcriptional and post-transcriptional level.

A limitation of our study was that the results are mainly based on predictions. Bioinformatics should be combined with experimentation to generate more accurate and reliable interpretations, however the in-silico analysis allows researchers to take an informed decision before proceeding in an expensive and time consuming experiment for further validation \[[@B42-medicina-55-00409]\]. The bioinformatics tools that have been used in this study have been tested for their performance as evidenced by the publications mentioned therein.

5. Conclusions {#sec5-medicina-55-00409}
==============

This study performed a thorough bioinformatic analysis of the CLDN16 gene and protein. Our main finding is the prediction that mitochondria are a probable subcellular compartment for the localization of the CLDN16 protein. The conditions under which the CLDN16 protein (or a fraction of it) reaches this organelle along with its possible functional role there, must be further investigated at the experimental level. Our results with respect to the *CLDN16* interactome underline its role in renal pathophysiology and highlight the functional dependence of the *CLDN16*-*CLDN19*-*CLDN14*-*CLDN10* genes. The predictions pertaining to the miRNAs, promoters/enhancers and CpG islands of the *CLDN16* gene provide indications for a strict regulation of its expression both transcriptionally and post-transcriptionally. Our report inculcates the idea of studying both the potential translocation of the CLDN16 protein to mitochondria and the functional role of the *CLDN16* gene regulatory network in kidney disorders other than FHHNC.
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![The display of the in-silico methodology steps that were applied in this study.](medicina-55-00409-g001){#medicina-55-00409-f001}

![The CpG island graph of the *CLDN16* gene as retrieved by the EMBOSS_CpGplot tool using the criteria: Observed/Expected ratio \>0.65; percent C + percent G \>55.00; length \>500. One island of unusual CG composition was identified (from 87--712, length 626).](medicina-55-00409-g002){#medicina-55-00409-f002}

![The results of the combined transmembrane topology and signal peptide prediction analysis as retrieved by the Phobius database.](medicina-55-00409-g003){#medicina-55-00409-f003}

![The secondary structure map of the CLDN16 protein as predicted by the PSIPRED v.3.3 software. Τhe intrinsic disorder predictor DISOPRED2 was also used to identify disordered regions.](medicina-55-00409-g004){#medicina-55-00409-f004}

![The results obtained by the DISPHOS 1.3 database regarding the prediction of phosphorylation sites within the CLDN16 protein selecting transport as the latter's functional class.](medicina-55-00409-g005){#medicina-55-00409-f005}

medicina-55-00409-t001_Table 1

###### 

The 25 potential transcription start positions predicted by the FPROM algorithm in the nucleotide sequence of *CLDN16*.

  ------------------- -----------------------------------------------------------------------------------------
  Promoter Position   49220 LDF ^1^: +9.953
  Promoter Position   559 LDF: +6.606 TATA box at 527 +3.708 GATTTAAA; Enchancer at: 622 Score: +10.194
  Promoter Position   58406 LDF: +5.233 TATA box at 58379 +4.957 TATATAGA
  Promoter Position   40172 LDF: +3.884 TATA box at 40145 +8.509 TATAAAAC
  Promoter Position   29232 LDF: +2.816 TATA box at 29200 +3.764 CATATAGA
  Promoter Position   27968 LDF: +2.513 TATA box at 27936 +7.471 TATATAAG
  Promoter Position   906 LDF: +1.626 TATA box at 865 +5.343 TATTAAAA; Enchancer at: 622 Score: +10.194
  Promoter Position   41678 LDF: +1.619 TATA box at 41643 +4.703 TATATATA; Enchancer at: 41701 Score: +10.937
  Promoter Position   3335 LDF: +1.403 TATA box at 3304 +5.535 TATATAAT
  Promoter Position   48910 LDF: +1.227 TATA box at 48877 +6.554 AATATAAA
  Promoter Position   44869 LDF: +0.663 TATA box at 44839 +4.130 TATAACAG
  Promoter Position   65626 LDF: +0.437 TATA box at 65594 +5.926 TATATAAA
  Promoter Position   69400 LDF: +0.423 TATA box at 69370 +7.797 TATAAAAG
  Promoter Position   32529 LDF: +0.116 TATA box at 32500 +8.328 TATAAAAA
  Promoter Position   51931 LDF: +0.008 TATA box at 51900 +3.876 TATTAAAA
  Promoter Position   4793 LDF: −0.042 TATA box at 4762 +3.800 CATAAAAC
  Promoter Position   81748 LDF: −0.140 TATA box at 81718 +4.492 CTTAAAAA
  Promoter Position   27538 LDF: −0.398 TATA box at 27508 +5.750 TATAAATT
  Promoter Position   50088 LDF: −0.458 TATA box at 50057 +5.632 CATATAAG
  Promoter Position   67124 LDF: −0.489 TATA box at 67094 +3.638 TTTAAATC
  Promoter Position   36521 LDF: −0.500 TATA box at 36492 +5.469 AATAAAAA
  Promoter Position   52521 LDF: −0.572 TATA box at 52491 +4.197 CATAAAAG
  Promoter Position   34329 LDF: −0.821 TATA box at 34301 +4.292 AATAAAAA
  Promoter Position   68333 LDF: −0.879 TATA box at 68303 +4.256 TTTAAAGG
  Promoter Position   85754 LDF: −0.905 TATA box at 85723 +5.966 TATTTAAA
  ------------------- -----------------------------------------------------------------------------------------

^1^ LDF: Linear Discriminant Function: value of Fisher's linear discriminant for the current promoter. A bigger value stands for more reliable promoter \[[@B9-medicina-55-00409]\].

medicina-55-00409-t002_Table 2

###### 

The gene interaction network (interactome) of the *CLDN16* gene as retrieved by the GeneMania database.

  Gene name     Gene Description
  ------------- ------------------------------------------------------
  *CLDN19*      Claudin 19
  *CLDN14*      Claudin 14
  *CLDN10*      Claudin 10
  *CLDN6*       Claudin 6
  *TJP1*        Tight Junction Protein 1
  *TJP3*        Tight Junction Protein 3
  *NPHS1*       NPHS1, Nephrin
  *PATJ*        PATJ, Crumbs Cell Polarity Complex Component
  *MYO3B*       Myosin IIIB
  *C14orf105*   Coiled-Coil Domain Containing 198
  *CLCNKA*      Chloride Voltage-Gated Channel Ka
  *CLCNKB*      Chloride Voltage-Gated Channel Kb
  *CTXN3*       Cortexin 3
  *FCAMR*       Fc Fragment Of IgA And IgM Receptor
  *CDH16*       Cadherin 16
  *LYG1*        Lysozyme G1
  *FBXO40*      F-Box Protein 40
  *KCNJ1*       Potassium Voltage-Gated Channel Subfamily J Member 1
  *TMEM178B*    Transmembrane Protein 178B
  *ADGRF3*      Adhesion G Protein-Coupled Receptor F3

The gene description has been provided by the GeneCards database.

medicina-55-00409-t003_Table 3

###### 

Functional enrichment analysis relative to disease of the *CLDN16* interactome. The results were obtained through ToppFun, an application of the ToppGene suite. FDR: False Discovery Rate; B and H: Benjamini-Hochberg; B and Y: BenjaminiYekutieli. Only the top 10 results are presented.

       ID            Name                                            Source                *p* Value        FDR B&H          FDR B&Y          Bonferroni       Genes from Input   Genes in Annotation
  ---- ------------- ----------------------------------------------- --------------------- ---------------- ---------------- ---------------- ---------------- ------------------ ---------------------
  1    C1846352      Increased urinary chloride                      DisGeNET Curated      7.888 × 10^−9^   1.037 × 10^−6^   6.376 × 10^−6^   2.074 × 10^−6^   [3]{.ul}           [5]{.ul}
  2    C1846351      Increased urinary potassium                     DisGeNET Curated      7.888 × 10^−9^   1.037 × 10^−6^   6.376 × 10^−6^   2.074 × 10^−6^   [3]{.ul}           [5]{.ul}
  3    C0085680      Hypochloremia (disorder)                        DisGeNET Curated      1.577 × 10^−8^   1.037 × 10^−6^   6.376 × 10^−6^   4.146 × 10^−6^   [3]{.ul}           [6]{.ul}
  4    C0595901      Serum chloride level decreased (finding)        DisGeNET Curated      1.577 × 10^−8^   1.037 × 10^−6^   6.376 × 10^−6^   4.146 × 10^−6^   [3]{.ul}           [6]{.ul}
  5    C1865279      Fetal polyuria                                  DisGeNET Curated      4.409 × 10^−8^   2.319 × 10^−6^   1.427 × 10^−5^   1.160 × 10^−5^   [3]{.ul}           [8]{.ul}
  6    C1846347      Renal salt wasting                              DisGeNET Curated      6.386 × 10^−7^   2.799 × 10^−5^   1.722 × 10^−4^   1.680 × 10^−4^   [3]{.ul}           [18]{.ul}
  7    cv:C2751312   Bartter syndrome, type 4b                       Clinical Variations   9.148 × 10^−7^   3.007 × 10^−5^   1.850 × 10^−4^   2.406 × 10^−4^   [2]{.ul}           [2]{.ul}
  8    OMIN:613090   Bartter syndrome, type 4b                       OMIM                  9.148 × 10^−7^   3.007 × 10^−5^   1.850 × 10^−4^   2.406 × 10^−4^   [2]{.ul}           [2]{.ul}
  9    C0740896      Hypokalemic hypochloremic metabolic alkalosis   DisGeNET Curated      2.740 × 10^−6^   6.226 × 10^−5^   3.830 × 10^−4^   7.207 × 10^−4^   [2]{.ul}           [3]{.ul}
  10   OMIN:602522   Bartter syndrome, type 4a                       OMIM                  2.740 × 10^−6^   6.226 × 10^−5^   3.830 × 10^−4^   7.207 × 10^−4^   [2]{.ul}           [3]{.ul}

medicina-55-00409-t004_Table 4

###### 

The putative miRNA bindind site predictions within the 3'-UTR region of CLDN16. The results were obtained from the miRWalk v.2.0 database. Only results with the two smaller *p*-values are presented.

  miRNA             Seed Length   *p*-Value
  ----------------- ------------- -----------
  hsa-miR-6076      11            0.0005
  hsa-miR-6878-3p   10            0.0020
  hsa-miR-328-5p    10            0.0020
  hsa-miR-559       10            0.0020
  hsa-miR-1256      10            0.0020
  hsa-miR-6859-5p   10            0.0020
  hsa-miR-95-5p     10            0.0020
